Premium
Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature
Author(s) -
Aditya K. Gupta,
Lynde,
Lauzon,
Mehlmauer,
Braddock,
; Miller,
Del Rosso
Publication year - 1998
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1998.02140.x
Subject(s) - terbinafine , medicine , dermatology , adverse effect , erythema multiforme , discontinuation , psoriasis , allylamine , dermatophyte , erythema , antifungal , itraconazole , surgery , pharmacology , chemistry , polyelectrolyte , organic chemistry , polymer
Terbinafine is an allylamine antifungal agent widely used to treat dermatophyte onychomycosis and dermatomycoses. We report 10 severe cutaneous adverse reactions associated with terbinafine therapy which required discontinuation of the antifungal agent: erythema multiforme (five patients), erythroderma (one), severe urticaria (one), pityriasis rosea (one) and worsening of pre‐existing psoriasis (two patients). The spectrum of cutaneous adverse effects associated with terbinafine therapy is reviewed. Patients should be counselled about discontinuing terbinafine at the onset of a cutaneous eruption and about seeking medical advice about further management.